Ergen K, Yildiz F, Ozcan M, Cekmen M, Ta Utkan T, Karakoc Y

Oxidative Stress Status, Metabolic Profile and Cardiovascular Risk Factors in Patients with Polycystic Ovary Syndrome

We aimed to investigate the relationships between Polycystic Ovary Syndrome (PCOS) and oxidative stress status, metabolic profile and cardiovascular risk factors in patients with polycystic ovary syndrome Methods: We measured Body Mass Index (BMI), glucose, cholesterol, triglyceride, HDL, LDL, high sensitive CRP (hsCRP), insulin, AST and ALT, Malondialdehyde (MDA), erythrocyte reduced glutathione (GSH), Nitric Oxide (NO) levels in PCOS patients and in normal individuals. We used spectrophotometrical method to determine glucose, cholesterol, triglyceride, HDL, LDL, AST and ALT levels. Nepholometrical method was used to measure hsCRP. Immunoassay method was used for insulin. Oxidant status was evaluated by using erythrocyte MDA and NO levels, while antioxidant status was evaluated by GSH levels. Results: Study population were consist of 32 women with PCOS (Study group) and 32 healthy volunteers (Control group). In study group, we found statistically higher levels of MDA, NO (p<0.001) and lower levels of GSH (p<0.001) compared to those of controls. hsCRP, insulin (p<0.001) and triglyceride (p<0.05) levels were statistically higher in study group. We also observed a statistically higher BMI in women with PCOS (p<0.05). Conclusion: Our results revealed that PCOS is associated with imbalanced oxidative/antioxidative status, impaired metabolic profile and increased cardiovascular risk factors.

Anahtar Kelimeler:

PCOS, oxidants, antioxidants, MDA, NO, GSH

Oxidative Stress Status, Metabolic Profile and Cardiovascular Risk Factors in Patients with Polycystic Ovary Syndrome

Keywords:

PCOS, oxidants, antioxidants, MDA, NO, GSH,

PDF

___

Lee H, Oh JY, Sung YA, Chung H, Cho WY. The prevalence and risk factors for glucose intolerance in young Korean women with polycystic ovary syndrome Endocrine. 2009;36(2):326-32.
Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003. Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25.
Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in non-obese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 1983;57(2):356-9.
Kuscu NK, Var A. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2009;88(5):612-7.
Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38(9):1165-74.
Sabuncu T, Vural H, Harma M, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem. 2001;34:407-13.
Gonzalez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:336-40.
Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol. 2005;3:28.
Verit FF, Erel O. Oxidative stress in non-obese women with polycystic ovary syndrome: correlations with endocrine and screening parameters. Gynecol Obstet Invest. 2008;65:233-9.
Bickerton AS, Clark N, Meeking D, Shaw KM, Crook M, Lumb P, Turner C, Cummings MH. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol. 2005;58(2):151-4.
Ruschitzka FT, Noll G, Luscher TF. The endothelium in coronary artery disease. Cardiology. 1997;88:3-19.
Carmina E, Orio F, Palomba S, Longo RA, Cascella T, Colao A, Lombardi G, Rini GB, Lobo RA. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med. 2006;119(4):356.e 1-6.
Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Paterakis T, Lekakis J, Panidis D. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest. 2006;36:691-7.
Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab. 2005;90:5711-6.
Karadeniz M, Erdogan M, Tamsel S, Zengi A, Alper GE, Caglayan O, Saygili F, Yilmaz C. Oxidative stress markers in young patients with polycystic ovary syndrome, the relationship between insulin resistances. Exp Clin Endocrinol Diabetes. 2008;116:231-5.
Cortas NK, Wakid NW. Determination of inorganic nitrate in serum and urine by a kinetic cadmium reduction method. Clin Chem. 1990;36:1440-3.
Uchiyama M, Mihara M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal. Biochem. 1978;34:271-8.
Tietz NW, ed, Textbook of clinical chemistry: Fairbanks V, Klee GG. Biochemical aspects of hematology. Philadelphia: W.B. Saunders, 1986;1532–4.
Lee H, Oh JY, Sung YA, Chung H, Cho WY. The prevalence and risk factors for glucose intolerance in young Korean women with polycystic ovary syndrome. Endocrine. 2009; 36(2):326-32.
Ambrosio G, Santoro G, Tritto I, Elia PP, Duilio C, Basso A, Scognamiglio A, Chiariello M. Effects of ischemia and reperfusion on cardiac tolerance to oxidative stress. Am J Physiol. 1992;262:23-30.
Cochrane CG. Cellular injury by oxidants. Am J Med. 1991;3C23S-3C30S.
Victor VM, Rocha M, Bañuls C, Sanchez-Serrano M, Sola E, Gomez M, Hernandez-Mijares A. Mitochondrial Complex I Impairment in Leukocytes from Polycystic Ovary Syndrome Patients with Insulin Resistance. J Clin Endocrinol Metab. 2009;94(9):3505-12.
Victor VM, Rocha M, Bañuls C, Sanchez-Serrano M, Sola E, Gomez M, Hernandez-Mijares A. DNA damage, DNA susceptibility to oxidation and glutathione level in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94(9):3505-12.
Yılmaz M, Bukan N, Ayvaz G, Karakoç A, Törüner F, Cakir N, Arslan M. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod. 2005;20(12):3333-40.
Erdogan M, Karadeniz M, Berdeli A, Alper G, Caglayan O, Yilmaz C. The relationship of the interleukin-6 -174 G>C gene polymorphism with oxidative stress markers in Turkish polycystic ovary syndrome patients. J Endocrinol Invest. 2008;31(7):624-9.
Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P. Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem 1997;43:1209-14.
Taylor BS, Kim YM, Wang Q, Shapiro RA, Billiar TR, Geller DA. Nitric oxide down regulates hepatocyte-inducible nitric oxide synthase gene expression. Arch Surg. 1997;132(11):1177-83.
Petrie JR, Ueda S, Webb DJ, Elliott HL, Connell JM. Endothelial nitric oxide production and insulin sensitivity. A physiological link with for pathogenesis of cardiovascular disease. Circulation. 1996;93(7):1331-3.
Su EN, Yu DY, Alder VA, Cringle SJ, Yu PK. Direct vasodilatory effect of insulin on isolated retinal arterioles. Invest Ophthalmol Vis Sci. 1996;37(13):2634-44.
Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM. Altered Vascular Function in Young Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2002;87(2):742- 6.
Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest. 1996;98(4):894-8.